Coherus BioSciences (CHRS) Reports Q3 Loss Per Share of $1.86
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.42 +7.58%
Financial Fact:
Occupancy and buying expenses: 81.34M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Occupancy and buying expenses: 81.34M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($1.86), versus ($1.79) reported last year. Revenue for the quarter came in at $7.2 million, versus $16.1 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Beike (BEKE) PT Raised to $23 at Morgan Stanley
- Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
